Clinical trial
Fulvestrant + Neratinib In Breast Cancer
NCT04901299
Study timeline
Study start (estimated)2023-07-01Date precision: month
Registry last updated2023-08-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Stage IV (Metastatic) Breast Cancerunresolved
Metastatic Breast Cancerunresolved
ER Positive Breast Cancerunresolved
PR-Positive Breast Cancerunresolved
HER2-negative Breast Cancerunresolved
Invasive Breast Cancerunresolved
Interventions
NERATINIBDRUG · verified · RxNorm: neratinib
FULVESTRANTDRUG · verified · RxNorm: fulvestrant
Sponsors & collaborators
Massachusetts General Hospitallead sponsor
Celcuity Inccollaborator
Puma Biotechnology, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04901299 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.